What is Lake Immunogenics?
Lake Immunogenics operates as a cornerstone provider in the life sciences industry, specializing in the development of custom antibodies, accredited animal housing, and comprehensive preclinical animal studies. The company distinguishes itself through its robust cGMP production services and an extensive portfolio of animal blood products derived from equines, bovines, llamas, and goats. With a footprint that encompasses over 90% of veterinary schools, the organization serves as a vital link in the supply chain for veterinary professionals and academic institutions. Their commitment to innovative science is reflected in their ability to provide high-quality biological materials that facilitate both clinical advancements and educational excellence in animal health.
How much funding has Lake Immunogenics raised?
Lake Immunogenics has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Lake Immunogenics
PPP
Public-Private Partnership
What's next for Lake Immunogenics?
With the successful acquisition of this capital, Lake Immunogenics is poised to enter a new phase of operational maturity. The strategic roadmap likely involves the expansion of its cGMP manufacturing capabilities to meet the rising demand for high-purity biological reagents. Furthermore, the company is expected to leverage this financial backing to enhance its preclinical research services, potentially diversifying its service offerings to include more complex diagnostic and therapeutic development support. As the firm transitions from its current growth stage, the focus will remain on maintaining its dominant market share while exploring new frontiers in veterinary immunology and biotechnology, ensuring that its infrastructure remains aligned with the evolving needs of global research institutions.
See full Lake Immunogenics company page
